SecBot SecBot

EIKN

Eikon Therapeutics, Inc.
Nasdaq· Biological Products, (No Diagnostic Substances)· Inc. DE· CIK 0001861123 Biotech & Drug Discovery
$5.91 −1.36 (−18.66%)
Oct 26 4:00 PM ET · prev $7.26
Market cap
$446.3M
Small cap
Consensus
Buy
83% Buy or better · 12 analysts
Median target
$27.50
+366% · range $4.00–32.00
Since first trade
−60.6%
from $15.00 · Feb 5
30 days
−25.3%
from $7.91
Range since listing
$5.91–16.26
at the low
Avg volume 20D
507.9K
shares / day
Short interest
6.29M
≈11.6% of shares · +15.4%
Days to cover
8.8
at average volume
Insider net
+$39.2M
1 buyer · 0 sellers · since Feb 6
New fund stakes
0
Q2 2026 13F · 0 exits
Filing reports
9
analyzed by SecBot
SecBot read BULLISH 9 reports · 90 days
Balance 0 bearish · 2 bullish · 7 neutral oldest → newest, height = score
Avg score ·High conf. 5/9
Strongest NEUTRAL Eikon Therapeutics presented initial and updated clinical data from its PARP1-selective (EIK1003, EIK1004)…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

  • InsidersBULLISH

    1 insider bought $39.2M at an average $17.74. No open-market sales. Price is 67% below their cost.

  • InstitutionsBULLISH

    Q2 2026: 10 added (0 new), 4 trimmed or exited.

  • AnalystsBULLISH

    10 of 12 rate it Buy or better. Median target $27.50 (+366%).

  • EstimatesFALLING

    Current-quarter EPS estimate −$1.556 → −$1.604 over 90 days. 2 up, 1 down in 30 days.

  • Short sellersBUILDING

    Short interest +15.4% to 6.29M shares. 8.8 days to cover, ≈11.6% of shares.

  • TrendDOWNTREND

    35% below its 50-day average. New closing low $5.91 on Oct 26.

Who's buying

13F· Q2 2026
0
new positions
0
exits
FundMoveSharesValue
FMR LLCADD4,993,906$65.2M
BlackRock, Inc.ADD4,281,425$55.9M
GEODE CAPITAL MANAGEMENT, LLCDOUBLED556,955$7.3M
ALLIANCEBERNSTEIN L.P.TRIM641,888$6.8M
STATE STREET CORPDOUBLED354,093$4.6M
UBS Group AGDOUBLED263,932$3.4M
CHARLES SCHWAB INVESTMENT MANAGEMENT INCADD182,105$2.4M
NORTHERN TRUST CORPDOUBLED175,927$2.3M

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

12 analysts
Buy 83% rate it Buy or better
Strong Buy3Buy7Hold1Sell0Strong Sell1
12-month targets · 6 analysts

Price is inside the target range. Median implies +366%.Targets as of Oct 26, 2026.

Recent actions
DateFirmActionRating
Oct 16, 2026HC Wainwright & Co.
INITIATE
INITIATEBuy
Aug 14, 2026Wedbush
MAINTAIN
MAINTAINUnderperform
May 12, 2026Wedbush
MAINTAIN
MAINTAINUnderperform

Insider ledger

Form 4
$39.2M
bought · 1 insider
$0
sold · 0 insiders
−66.7%
vs their $17.74 cost
DateInsiderTypeValue
Sep 3, 2026
Column Group IV GP, LP
10%+ Owner
BUY$1.0M
Mar 2, 2026
FRAZIER KENNETH C
Director
AWARD25,873 sh
Mar 2, 2026
Klobuchar Michael A
Chief Operating Officer
AWARD87,157 sh
Mar 2, 2026
Thorner Benjamin Bruno
See Remarks
AWARD67,044 sh
Mar 2, 2026
Bowie Alfred Lloyd Jr.
Chief Financial Officer
AWARD67,044 sh
Mar 2, 2026
Huffines Robert Luther
Director
AWARD25,873 sh
Mar 2, 2026
Baynes Roy D.
Chief Medical Officer
AWARD134,088 sh
Mar 2, 2026
PERLMUTTER ROGER M
See remarks
AWARD268,176 sh

Earnings setup

Estimates
−$1.60
EPS estimate, this quarter
−3%
estimate change, 90 days
2↑ 1↓
revisions, 30 days
Current-quarter EPS estimate
PeriodEPS est.Range30D rev.Revenue
Current Q-$1.60-$1.74–-$1.33-1.8%$0.00
Next Q-$1.61-$1.83–-$1.38-3.3%$0.00
Current FY-$6.58-$7.40–-$5.84-2.6%$0.00
Next FY-$6.69-$8.49–-$4.86-5.7%$0.00

Short side

FINRA· Sep 30, 2026
6,294,602
shares short
+15.4%
vs prior settlement
8.8
days to cover
≈11.6%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 26, 2026 SEC
🔒 Fresh report (last 24h), subscribers only
Oct 26, 2026 Press
🔒 Fresh report (last 24h), subscribers only
Oct 26, 2026 FDA
🔒 Fresh data, subscribers only
Oct 23, 2026 SEC
Eikon Therapeutics presented initial and updated clinical data from its PARP1-selective (EIK1003, EIK1004) and WRN…
8-K — Impact 4/10
Oct 7, 2026 SEC
FMR LLC (Fidelity) filed an amended Schedule 13G disclosing beneficial ownership of 5,520,152 shares of Eikon…
SC 13G/A — Impact 3/10
Sep 3, 2026 Press
Eikon Therapeutics appointed Dr. Ching-Pin Chang as EVP and Chief Scientific Officer. Dr. Chang joins from Bristol…
Impact 3/10
Sep 3, 2026 Insider
Column Group IV GP, LP bought 89,200 shares
10%+ Owner @ $11.56 ($1.0M)
Jun 30, 2026 Inst.
FMR LLC — ADD
4,993,906 shares ($65.2M)
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Recent
Oct 26, 2026
FDA
🔒 Fresh data, subscribers only
Oct 18, 2026
Press release
Eikon Therapeutics Announces Availability of Seven Abstracts for Presentation at the European Society for Medical Oncology Congress
Presentations to cover updates across Eikon’s clinical pipeline including: Updated data from TeLuRide-005, an ongoing open-label Phase 2 trial of...
Oct 15, 2026
Press release
Eikon Therapeutics Submits IND for Novel Androgen Receptor Antagonist EIK1006 in Prostate Cancer
EIK1006 is a novel androgen receptor (AR) antagonist that is structurally unrelated to currently available lutamide-class antagonists....
Sep 3, 2026
Leadership
Eikon Therapeutics Appoints Ching-Pin Chang, M.D., Ph.D. as Executive Vice President and Chief Scientific Officer
MILLBRAE, Calif., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. (Nasdaq: EIKN) (“Eikon”), a late-stage clinical biopharmaceutical…
Sep 1, 2026
Trial readout
T-90d Trial Readout: EIK1001 (Phase 2)
Trial: A Phase 2 Study of EIK1001 in Combo With Pembrolizumab and Chemotherapy in Patients With Stage 4 NSCLC Sponsor: Eikon Therapeutics Phase…

SecBot reports

9 filings · 4 press releases · 1 bullish · 0 bearish · 8 neutral
All EIKN filing & press-release reports (13)